Orchard discreetly axes license for 'bubble boy' gene therapy, despite recent positive long-term data update
Less than a month after publishing positive long-term data for an experimental gene therapy, Orchard Therapeutics has quietly terminated its licensing agreement over the program.
In an 8-K filing to the SEC last Friday, Orchard reported that it is ending the license related to its OTL-101 candidate, in development to treat adenosine deaminase severe combined immunodeficiency or ADA-SCID, known colloquially as “bubble boy syndrome.” It’s a rare genetic disease where patients have almost no immune system whatsoever.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.